{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:40:24Z","timestamp":1789274424782,"version":"build-2803163510"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Viamet Pharmaceuticals, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute vulvovaginal candidiasis (VVC) is common among women, but current azole antifungal treatments are often associated with safety and resistance issues. VT-1161 (oteseconazole) is an oral agent with increased selectivity for fungal CYP51. In this phase 2 clinical study, we evaluated the efficacy and safety of VT-1161 vs fluconazole in participants with moderate to severe acute VVC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants presenting with an acute episode of VVC (n\u2005=\u200555) were randomized to receive VT-1161 300 mg once daily (q.d.) for 3 days, 600 mg q.d. for 3 days, or 600 mg twice daily (b.i.d.) for 3 days or to receive a single dose of fluconazole 150 mg (FDA-approved dose to treat acute VVC). Participants were followed for 6 months. The primary outcome was the proportion of participants with therapeutic (clinical and mycological) cure at day 28.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A larger proportion of participants in the per-protocol population experienced therapeutic cure in the VT-1161 300 mg q.d. (75.0%), VT-1161 600 mg q.d. (85.7%), and VT-1161 600 mg b.i.d. (78.6%) groups vs the fluconazole group (62.5%); differences were not statistically significant. At 3 and 6 months, no participants in the VT-1161 groups vs 28.5% and 46.1% in the fluconazole group, respectively, had evidence of mycological recurrence. No serious adverse events or treatment-emergent adverse events leading to discontinuation were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The majority of participants across all treatment groups achieved therapeutic cure at day 28. VT-1161 was well tolerated at all dose levels through 6 months of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT01891331.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1204","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T15:26:20Z","timestamp":1597332380000},"page":"e1518-e1524","source":"Crossref","is-referenced-by-count":54,"title":["A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis"],"prefix":"10.1093","volume":"73","author":[{"given":"Stephen R","family":"Brand","sequence":"first","affiliation":[{"name":"Viamet Pharmaceuticals, Durham, North Carolina, USA"},{"name":"Mycovia Pharmaceuticals, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack D","family":"Sobel","sequence":"additional","affiliation":[{"name":"School of Medicine, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nyirjesy","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A","family":"Ghannoum","sequence":"additional","affiliation":[{"name":"Center for Medical Mycology, Case Western Reserve University, and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Schotzinger","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten P","family":"Degenhardt","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Durham, North Carolina, USA"},{"name":"Mycovia Pharmaceuticals, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"2021100522230337800_CIT0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajog.2015.06.067","article-title":"Recurrent vulvovaginal candidiasis","volume":"214","author":"Sobel","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"2021100522230337800_CIT0002","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa033114","article-title":"Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis","volume":"351","author":"Sobel","year":"2004","journal-title":"N Engl J Med"},{"key":"2021100522230337800_CIT0003","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1358\/dot.2003.39.10.799473","article-title":"Clinical impact of drug-drug interactions with systemic azole antifungals","volume":"39","author":"Bates","year":"2003","journal-title":"Drugs Today (Barc)"},{"key":"2021100522230337800_CIT0004","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4065\/mcp.2011.0247","article-title":"Current concepts in antifungal pharmacology","volume":"86","author":"Lewis","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"2021100522230337800_CIT0005","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021100522230337800_CIT0006","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/AOG.0b013e31827307b2","article-title":"Fluconazole-resistant Candida albicans vulvovaginitis","volume":"120","author":"Marchaim","year":"2012","journal-title":"Obstet Gynecol"},{"key":"2021100522230337800_CIT0007","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jama.2015.17844","article-title":"Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth","volume":"315","author":"M\u00f8lgaard-Nielsen","year":"2016","journal-title":"JAMA"},{"key":"2021100522230337800_CIT0008","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1016\/j.bmcl.2014.05.068","article-title":"Design and optimization of highly-selective fungal CYP51 inhibitors","volume":"24","author":"Hoekstra","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"2021100522230337800_CIT0009","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1128\/AAC.03707-14","article-title":"The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme","volume":"58","author":"Warrilow","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021100522230337800_CIT0010","volume-title":"Diflucan (Fluconazole Tablets)","year":"2011"},{"key":"2021100522230337800_CIT0011","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1067\/mob.2001.115116","article-title":"Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole","volume":"185","author":"Sobel","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"2021100522230337800_CIT0012","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2008","edition":"3rd ed"},{"key":"2021100522230337800_CIT0013","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Centers for Disease Control and Prevention","year":"2015","journal-title":"Recommendations Rep"},{"key":"2021100522230337800_CIT0014","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1289\/ehp.5785","article-title":"Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14 alpha-demethylase and aromatase","volume":"111","author":"Zarn","year":"2003","journal-title":"Environ Health Perspect"},{"key":"2021100522230337800_CIT0015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: a persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"2021100522230337800_CIT0016","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1128\/JCM.00946-09","article-title":"Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007","volume":"47","author":"Pfaller","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2021100522230337800_CIT0017","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0140-6736(02)08162-X","article-title":"Antifungal drug resistance of pathogenic fungi","volume":"359","author":"Kontoyiannis","year":"2002","journal-title":"Lancet"},{"key":"2021100522230337800_CIT0018","doi-asserted-by":"crossref","first-page":"624.e1","DOI":"10.1016\/j.ajog.2018.03.001","article-title":"A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis","volume":"218","author":"Brand","year":"2018","journal-title":"Am J Obstet Gynecol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1204\/33890841\/ciaa1204.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/7\/e1518\/40511243\/ciaa1204.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/7\/e1518\/40511243\/ciaa1204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T18:41:13Z","timestamp":1633718473000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/7\/e1518\/5895051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":18,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,8,20]]},"published-print":{"date-parts":[[2021,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1204","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2020,8,20]]}}}